Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mefenamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.97 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.97 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.97 |
| ▸ | DHFR | P00374 | 1/20 | 0.97 |
| ▸ | MPO | P05164 | 1/20 | 0.97 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mefenamic Acid SCHEMBL29465887 | 0.98 | PTGS2 (1.00) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL3544 | 0.98 | PTGS2 (1.00) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL6421234 | 0.98 | PTGS2 (1.00) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL29350572 | 0.98 | PTGS2 (1.00) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL29355128 | 0.98 | PTGS2 (1.00) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL27621964 | 0.97 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL28663310 | 0.97 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL28036729 | 0.97 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL16179956 | 0.97 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A | |
| Mefenamic Acid SCHEMBL29282578 | 0.97 | PTGS2 (0.97) | PTGS2AKR1C3LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| EP-3456710-B1 | NOVEL PROSTAGLANDIN DERIVATIVE | AGC INC (JP) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020027200-A1 | THERAPEUTIC AGENT FOR CARTILAGE DISEASE | 小野薬品工業株式会社 | 2020-02-06 | — | — | WO | disclosed |
| CN-110655502-A | Acid addition salts of Trk inhibiting compounds | 小野药品工业株式会社 | 2020-01-07 | — | — | CN | disclosed |
| US-10494338-B2 | Prostaglandin derivative | AGC Inc. (JP) | 2019-12-03 | — | — | US | disclosed |
| CN-106573913-B | Inhibit the acid-addition salts of the compound of Trk | 小野药品工业株式会社 | 2019-11-19 | — | — | CN | disclosed |
| CN-106986857-B | Trk inhibiting compound | 小野药品工业株式会社 | 2019-07-05 | — | — | CN | disclosed |
| US-20190135743-A1 | NOVEL PROSTAGLANDIN DERIVATIVE | AGC Inc. (JP) | 2019-05-09 | — | — | US | disclosed |
| EP-3456710-A1 | NOVEL PROSTAGLANDIN DERIVATIVE | AGC INC. (JP) | 2019-03-20 | — | — | EP | disclosed |
| CN-106986857-A | Trk inhibiting compounds | 小野药品工业株式会社 | 2017-07-28 | — | — | CN | disclosed |
| EP-1609480-A1 | REMEDY FOR SPINAL CANAL STENOSIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-28 | — | — | EP | disclosed |
| CN-1656085-A | Carboxylic acid compound and pharmaceutical preparation containing the same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-17 | — | — | CN | disclosed |
| EP-1522314-A1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-13 | — | — | EP | disclosed |
| CN-1578767-A | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-02-09 | — | — | CN | disclosed |
| US-20050004097-A1 | Indole derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20040198831-A1 | Remedial agent for arthrosis deformans | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1424335-A1 | INDOLE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1424325-A1 | INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1421934-A1 | REMEDIAL AGENT FOR ARTHROSIS DEFORMANS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10494338-B2 | Prostaglandin derivative | PTGIR, PTGIS, PTGS1 | PTGS2 6/4885PTGS1 3/4885AKR1C3 532/4885 |
| US-20050004097-A1 | Indole derivatives | IDO1, IDO2, PTGIR | PTGS2 71/4885PTGS1 21/4885AKR1C3 1002/4885 |
| US-20190135743-A1 | NOVEL PROSTAGLANDIN DERIVATIVE | PTGIR, PTGIS, PTGER1 | PTGS2 8/4885PTGS1 4/4885AKR1C3 650/4885 |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | IDO1, IDO2, PTGIR | PTGS2 51/4885PTGS1 18/4885AKR1C3 1279/4885 |
| US-20040198831-A1 | Remedial agent for arthrosis deformans | MMP1, MMP3, MMP11 | PTGS2 151/4885PTGS1 33/4885AKR1C3 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.